Physicians’ assessment of the Bavarian drug-expenditure control system: a qualitative study

Author:

Zeschick Nikoletta,Gollnick Julia,Muth Julia,Hörbrand Franziska,Killian Peter,Donner-Banzhoff Norbert,Kühlein Thomas,Sebastião MariaORCID

Abstract

Abstract Background In 2014 a new system for drug expenditures, the Wirkstoffvereinbarung (WSV, English: Active substance agreement) was implemented in Bavaria. In pre-defined indication groups, economic prescription of medications shall be enabled based on the selection, quantity, and proportion of an individual drug. Ambulatory care physicians receive quarterly trend reports on their prescribing behavior. This study examines physicians’ perceptions of the WSV. Methods Qualitative interviews (n = 20) and seven focus groups (n = 36) were conducted with ambulatory care physicians (e.g. general practitioners, cardiologists, pulmonologists). The methodology followed Qualitative Content Analysis. Results Physicians generally accepted the necessity of prescribing economically. The majority of them rated the WSV positively and better than the previous system. As an improvement, they especially named timely feedback in form of easily understandable trend reports, encouraging self-reflection as well as allowing early control options. Problems perceived were drug discount contracts that were strongly criticized as leading to patients mixing up medications. Some perceived constraints of therapeutic freedom. Conclusions The implementation of the WSV is mostly viewed positively by physicians. The restrictions of therapeutic freedom partially perceived might be met by improved information on the reasons why some drugs are rated as less economical than others. Trial registration number Main ID: DRKS00019820 (German Register of Clinical Studies and World Health Organization).

Funder

Gemeinsame Bundesausschuss

Friedrich-Alexander-Universität Erlangen-Nürnberg

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Reference39 articles.

1. OECD. Pharmaceutical expenditure 2020. OECD Publishing. 2020. https://data.oecd.org/healthres/pharmaceutical-spending.htm. Accessed 10 Oct 2022.

2. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21:89–103.

3. Niehaus F, Finkenstädt V. Deutschland - ein im internationalen Vergleich teures Gesundheitswesen? [Germany - an expensive health care system in international comparison?] Wissenschaftliches Insitut der PFV (WIP). 2009. http://www.wip-pkv.de/fileadmin/DATEN/Veroeffentlichungen/Deutschland_ein_teures_Gesundheitswesen.pdf Accessed 10 Oct 2022.

4. Korzilius H. Deutsches Gesundheitssystem: Hohe Kosten, durchschnittliche Ergebnisse [German health system: high costs, average results.]. Dtsch Arztebl Int. 2019;116:2283–4.

5. GKV-Spitzenverband. Kennzahlen der gesetzlichen Krankenversicherung [Key figures of the statutory health insurance] 2021. https://gkv-spitzenverband.de/media/grafiken/gkv_kennzahlen/kennzahlen_gkv_2021_q2/20210901_GKV_Kennzahlen_Booklet_Q2-2021_300dpi_barrierefrei.pdf. Accessed 10 Oct 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3